陈浩(加拿大)(0级持证会员) 发表于 2013-6-16 10:09:03

国内国际一类新药项目

<DIV><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 1.0pt; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA"><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 1.0pt; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">&nbsp;
<DIV><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 1.0pt; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">注射用重组人血清白蛋白<SPAN lang=EN-US>/</SPAN>干扰素融合蛋白，</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 1.0pt; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">现在已经拿到临床批件，由科研团队正在进行1期临床，现在有25个病号，100%效果，预计2年内拿到新药批文。</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 1.0pt; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">此项目需要融资1.5亿。其中0.5亿用于完成3期临床，1亿元用于建厂，销售。在完成3期临床，拿到新药批文后该药已经可以卖批文3-5个亿。</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 1.0pt; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">中国现有约<SPAN lang=EN-US>60</SPAN>余家企业生产和销售常规重组干扰素这两个品种。常规重组干扰素每天或每<SPAN lang=EN-US>2</SPAN>天用药<SPAN lang=EN-US>1</SPAN>针，需要连续用药<SPAN lang=EN-US>6</SPAN>个约至<SPAN lang=EN-US>1</SPAN>年。现有的美国罗氏的“派罗欣”（<SPAN lang=EN-US>PEG</SPAN>化重组人干扰素）需要每周注射<SPAN lang=EN-US>1</SPAN>次。而新药则是每<SPAN lang=EN-US>2</SPAN>周用药<SPAN lang=EN-US>1</SPAN>次，将极大提高患者的依从度和大大降低患者的治疗费用和社会医疗资源。新药的生产成本仅是现有常规重组干扰素的<SPAN lang=EN-US>1/2</SPAN>成本，也是<SPAN lang=EN-US>PEG</SPAN>化长效重组干扰素的<SPAN lang=EN-US>1/20</SPAN>。现有具有极好的经济和社会效益。中国现有<SPAN lang=EN-US>1.3</SPAN>亿人为肝炎病毒感染者，干扰素是唯一的特效药。但由于常规干扰素的注射用药频繁，患者不能坚持用药，同时常规重组干扰素具有十分明显的毒副作用，而新药可降低用药量，减少毒副作用。可用于各种慢性肝炎患者的治疗和多种癌症的治疗.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 1.0pt; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA"><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 1.0pt; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">根据现有的常规重组干扰素药物在全球每年销售额为<SPAN lang=EN-US>$100</SPAN>亿美元<SPAN lang=EN-US>;</SPAN>在中国每年的销售额为￥<SPAN lang=EN-US>100</SPAN>亿人民币左右。</SPAN></SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 1.0pt; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA"></SPAN>&nbsp;</DIV>
<DIV><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 1.0pt; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA"></SPAN>&nbsp;</DIV>
<DIV><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 宋体; mso-font-kerning: 1.0pt; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">可联系我邮箱：<A href="mailto:1053668646@qq.com">1053668646@qq.com</A></SPAN></DIV></SPAN></SPAN></DIV><ins class="modify">[本话题由 scotchen 于 2013-06-16 10:16:13 编辑]</ins>

Angela(澳大利亚) 发表于 2015-12-10 09:31:26

回复不了你的人私聊

刘雅倩(0级持证会员) 发表于 2016-2-29 12:46:48

不好意思，我回不了私信哪

唐(瑞士) 发表于 2017-2-5 11:24:43

回复不了私信

况珊 发表于 2017-6-18 12:19:59

不好意思 我回不了 私信

唐仲文(澳大利亚) 发表于 2017-6-18 14:18:40

是什么公司研发的？
页: [1]
查看完整版本: 国内国际一类新药项目